ES2091906T3 - Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia. - Google Patents

Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia.

Info

Publication number
ES2091906T3
ES2091906T3 ES91901056T ES91901056T ES2091906T3 ES 2091906 T3 ES2091906 T3 ES 2091906T3 ES 91901056 T ES91901056 T ES 91901056T ES 91901056 T ES91901056 T ES 91901056T ES 2091906 T3 ES2091906 T3 ES 2091906T3
Authority
ES
Spain
Prior art keywords
omega
ischemia
treatment
neuronal damage
conotoxin peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91901056T
Other languages
English (en)
Inventor
George P Miljanich
Robert S Bitner
Stephen S Bowersox
James A Fox
Karen L Valentino
Donald H Yamashiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Corp PLC
Original Assignee
Neurex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurex Corp filed Critical Neurex Corp
Application granted granted Critical
Publication of ES2091906T3 publication Critical patent/ES2091906T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA EFECTIVA EN LA REDUCCION DEL DAÑO NEURONAL RELACIONADO CON UNA CONDICION ISQUEMICA EN UNAS ESPECIES MAMIFERAS. LA COMPOSICION INCLUYE UN CANAL CALCICO NEURONAL COMPUESTO ANTAGONISTA EFECTIVO PARA BLOQUEAR LA LIBERACION DE NOREPINEPHRINE EN CELDAS NEURONALES CNS MAMIFERAS, Y CARACTERIZADAS POR UNA ALTA AFINIDAD ESPECIFICA DE UNION A UNA PROTEINA DE UNION MVIIA OMEGACONOTOXIN. TAMBIEN SE PRESENTAN NUEVOS PEPTIDOS OMEGA-CONOTOXIN.
ES91901056T 1989-11-22 1990-11-21 Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia. Expired - Lifetime ES2091906T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/440,094 US5051403A (en) 1989-11-22 1989-11-22 Method of treating ischemia-related neuronal damage

Publications (1)

Publication Number Publication Date
ES2091906T3 true ES2091906T3 (es) 1996-11-16

Family

ID=23747411

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91901056T Expired - Lifetime ES2091906T3 (es) 1989-11-22 1990-11-21 Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia.

Country Status (11)

Country Link
US (1) US5051403A (es)
EP (1) EP0593450B1 (es)
JP (1) JP3809184B2 (es)
AT (1) ATE140388T1 (es)
AU (1) AU648052B2 (es)
CA (1) CA2045473C (es)
DE (1) DE69027865T2 (es)
DK (1) DK0593450T3 (es)
ES (1) ES2091906T3 (es)
GR (1) GR3021087T3 (es)
WO (1) WO1991007980A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846757A (en) * 1988-04-04 1998-12-08 Sibia Neurosciences, Inc. Human calcium channel α1, α2, and β subunits and assays using them
US6653097B1 (en) 1991-08-15 2003-11-25 Merck & Co., Inc. Human calcium channel compositions and methods
US5874236A (en) * 1988-04-04 1999-02-23 Sibia Neurosciences. Inc. DNA encoding human calcium channel α-1A, β1, β-2, and β-4 subunits, and assays using cells that express the subunits
US20040018510A1 (en) 1990-11-08 2004-01-29 Merck & Co., Inc. Human calcium channel compositions and methods
US6387696B1 (en) 1988-04-04 2002-05-14 Merck & Co., Inc. Human calcium channel compositions and methods
US5851824A (en) * 1988-04-04 1998-12-22 Sibia Neurosciences, Inc. Human calcium channel α-1C/α-1D, α-2, β-1, and γsubunits and cells expressing the DNA
US5876958A (en) * 1988-04-04 1999-03-02 Sibia Neurosciences, Inc. Assays of cells expressing human calcium channels containing α1 β subunits
EP0424397B1 (en) * 1988-04-04 1996-06-19 The Salk Institute Biotechnology Industrial Associates, Inc. Calcium channel compositions and methods
US5407820A (en) * 1988-04-04 1995-04-18 The Salk Institute Biotechnology/Industrial Associates, Inc. Calcium channel α-2 subunit DNAs and cells expressing them
US6096514A (en) * 1988-04-04 2000-08-01 Sibia Neurosciences, Inc. Human calcium channel compositions and methods
US5386025A (en) * 1990-02-20 1995-01-31 The Salk Institute Biotechnology/Industrial Associates Calcium channel compositions and methods
US5559095A (en) * 1989-11-22 1996-09-24 Neurex Corporation Delayed treatment method of reducing ischemia-related neuronal damage
US5264371A (en) * 1989-11-22 1993-11-23 Neurex Corporation Screening method for neuroprotective compounds
WO1993010145A1 (en) * 1991-11-12 1993-05-27 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
SG50624A1 (en) * 1991-12-30 1998-07-20 Neurex Corp Methods of producing analgesia and enhancing opiate analgesia
EP0556160A3 (en) * 1992-02-11 1993-10-27 Sandoz Ag Insecticidal toxins from plectreurys tristis
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5514774A (en) * 1993-06-29 1996-05-07 University Of Utah Research Foundation Conotoxin peptides
US5591821A (en) * 1993-07-16 1997-01-07 The University Of Utah Omega-conotoxin peptides
US6090623A (en) * 1993-08-11 2000-07-18 Merck & Co., Inc. Recombinant human calcium channel β4 subunits
US5739276A (en) * 1994-10-07 1998-04-14 University Of Utah Research Foundation Conotoxin peptides
US5670622A (en) * 1996-02-15 1997-09-23 University Of Utah Research Foundation Conotoxin peptide PIIIA
DK0835126T3 (da) * 1995-06-27 2003-07-14 Elan Pharm Inc Sammensætninger og formuleringer til fremstilling af analgesimidler og til hamning af fremadskridende neuropatiske amertelidelser
US6054429A (en) * 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
US5965534A (en) * 1995-11-22 1999-10-12 Alcon Laboratories, Inc. Use of ω-conotoxin analogs for treating retinal and optic nerve head damage
US5672682A (en) * 1996-03-18 1997-09-30 University Of Utah Research Foundation Conotoxin peptide PVIIA
US6528630B1 (en) 1997-12-03 2003-03-04 Merck & Co., Inc. Calcium channel compositions and methods
US6379882B1 (en) 1998-09-14 2002-04-30 Elan Pharmaceuticals, Inc. Method for selecting compounds for treating ischemia-related cellular damage
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
AU6415999A (en) * 1998-10-06 2000-04-26 Cognetix, Inc. Kappa-a conopeptides and uses therefor
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
US6855805B2 (en) 1999-01-22 2005-02-15 University Of Utah Research Foundation α-conotoxin peptides
JP2003525582A (ja) 1999-01-22 2003-09-02 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション アルファ−コノトキシンペプチド
IL148053A0 (en) * 1999-08-10 2002-09-12 Uab Research Foundation Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occuring conotoxins
US6762165B2 (en) 1999-12-30 2004-07-13 University Of Utah Research Foundation O-superfamily conotoxin peptides
ATE547424T1 (de) 2002-12-02 2012-03-15 Xenome Ltd Chi-conotoxinpeptide mit einer n-terminalen pyroglutaminsäure
EP2412719A1 (en) 2002-12-02 2012-02-01 Xenome Ltd Chi-conotoxin peptides
US20090062211A1 (en) * 2003-03-05 2009-03-05 Florida Atlantic University Conopeptides and methods of use
US20060019892A1 (en) * 2003-03-05 2006-01-26 Florida Atlantic University Conopeptides and methods of use
WO2005032556A1 (en) 2003-10-02 2005-04-14 Elan Pharmaceuticals, Inc. Method for reducing pain
JP5319920B2 (ja) * 2004-09-10 2013-10-16 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ナトリウムおよび／またはカルシウムチャンネル選択的調節因子として活性のある医薬の製造のための（ハロベンジルオキシ）ベンジルアミノ−プロパンアミドの使用
CN1304422C (zh) * 2005-09-15 2007-03-14 浙江大学 非酰胺化ω－芋螺毒素M ⅦA 及其制备方法和应用
JP5271087B2 (ja) * 2005-12-22 2013-08-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー カルシウム及び／又はナトリウムチャネル調節物質としての２−フェニルエチルアミノ誘導体
PL2155663T3 (pl) * 2007-06-15 2018-06-29 Newron Pharmaceuticals S.P.A. Podstawione pochodne 2-[2-(fenylo)etyloamino]alkanoamidu oraz ich zastosowanie jako modulatorów kanałów sodowych i (lub) wapniowych
US8765677B2 (en) 2009-09-21 2014-07-01 The University Of Queensland Omega conotoxin peptides
WO2013000651A1 (en) 2011-06-27 2013-01-03 Newron Pharmaceuticals S.P.A. Fluorinated arylalkylaminocarboxamide derivatives
JP6731044B2 (ja) 2015-05-22 2020-07-29 クレムソン・ユニバーシティ・リサーチ・ファウンデーション 生物付着の抑止において用いるためのコノトキシンペプチド

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US4950739A (en) * 1988-02-10 1990-08-21 New York University Membrane calcium channels and factors and methods for blocking, isolating and purifying calcium channels

Also Published As

Publication number Publication date
AU6964091A (en) 1991-06-26
WO1991007980A1 (en) 1991-06-13
JP3809184B2 (ja) 2006-08-16
DK0593450T3 (da) 1996-11-25
EP0593450B1 (en) 1996-07-17
GR3021087T3 (en) 1996-12-31
JPH05501715A (ja) 1993-04-02
HK1006810A1 (en) 1999-03-19
DE69027865T2 (de) 1997-01-02
AU648052B2 (en) 1994-04-14
US5051403A (en) 1991-09-24
DE69027865D1 (de) 1996-08-22
ATE140388T1 (de) 1996-08-15
EP0593450A1 (en) 1994-04-27
CA2045473A1 (en) 1991-05-23
CA2045473C (en) 2002-09-17

Similar Documents

Publication Publication Date Title
ES2091906T3 (es) Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia.
DK0386997T3 (da) Anvendelse af 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamin-derivater i behandlingen af psykose, inflammation og som immunosuppressive midler
MX9202436A (es) Composiciones para el cuidado del cabello y metodo para su preparacion.
MX9201141A (es) Ciclosporinas cristalinas, procedimiento para su produccion y composicion farmaceutica que las contiene.
IT8847556A0 (it) Derivati peptidici, loro preparazione e loro impiego come medicamenti
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
MX9206306A (es) Peptidos, procedimiento para su produccion y composicion farmaceutica que los contiene.
DE3889536D1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
BR9907995A (pt) Métodos imunológicos para modular miostatina em sujeitos vertebrados
IT8947823A0 (it) Derivati peptidici, loro preparazione e loro impiego come medicamenti
FI931499A7 (fi) Syklopeptidit, menetelmä niiden valmistamiseksi ja niiden käyttö lääke aineina
NO873699L (no) Polypeptid som er egnet til dempning, behandling og diagnostisering av autoimmune lidelser saasom leddbetennelser.
ES2103854T3 (es) Peptidos con actividad organo protectiva, procedimiento para la preparacion de los mismos y su utilizacion en la terapia.
ES2156107T3 (es) Un fgf-4 no glicosilado y composiciones que lo contienen.
IT8847871A0 (it) Ne e loro impiego come medicamenti derivati peptidici,loro preparazio-
DK0563085T3 (da) Hidtil ukendte præparater
ITRM910002A0 (it) Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
DE69022957D1 (de) Spanner.
MX9204613A (es) Nitratos organicos, procedimientos para su preparacion y su uso en el tratamiento de enfermedades cardiovasculares
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
NO931011L (no) 7-okso-7h-pyrido(1,2,3-de)(1,4)benzoksacin-6-karbonsyrer og -estere
BR9407530A (pt) Estrutura de peptídeo com múltiplas ramifacações medicamento uso de uma estrutura de peptídeo com múltiplas ramificações metodo para o tratamento de infecções por HIV processo para a preparação de uma estrutura de peptídeo com múltiplas ramificações
KR900007816A (ko) 사이클로프로필-치환된 아졸릴메틸카비놀, 이의 제조방법 및 약제로서의 이의 용도
ES2072869T3 (es) Uso de derivados de la 1,4-dihidropiridina en el tratamiento del alcoholismo.
CA2071956A1 (en) Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 593450

Country of ref document: ES